Baricitinib Patent Expiration
Baricitinib is Used for treating severe alopecia areata, COVID-19 in hospitalized adults requiring supplemental oxygen, ventilation, or ECMO, and rheumatoid arthritis. It was first introduced by Eli Lilly And Co
Baricitinib Patents
Given below is the list of patents protecting Baricitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Olumiant | US11045474 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections | Nov 30, 2032 | Eli Lilly And Co |
| Olumiant | US9089574 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | Nov 30, 2032 | Eli Lilly And Co |
| Olumiant | US8158616 | Azetidine and cyclobutane derivatives as JAK inhibitors | May 31, 2032 | Eli Lilly And Co |
| Olumiant | US11806555 | Methods for treating hair loss disorders | Nov 02, 2031 | Eli Lilly And Co |
| Olumiant | US9737469 | Methods for treating hair loss disorders | Nov 02, 2031 | Eli Lilly And Co |
| Olumiant | US8420629 | Azetidine and cyclobutane derivatives as JAK inhibitors | Mar 10, 2029 | Eli Lilly And Co |
Baricitinib's Family Patents
Explore Our Curated Drug Screens
Baricitinib Generics
Several generic applications have been filed for Baricitinib.
Given below is the list of companies who have filed for Baricitinib generic.
1. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Baricitinib. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Discontinued | ORAL | N/A | Jul 22, 2024 |
| 2MG | tablet | Discontinued | ORAL | N/A | Jul 22, 2024 |